Cardiovascular

What is Pulmonary Hypertension?

Pulmonary Hypertension is an umbrella term for a range of conditions categorised by an increase in pulmonary arterial pressure associated with various clinical conditions.¹ The Dana point classification table distinguishes between the types of Pulmonary Hypertension.

ADEMPAS (riociguat) is licensed as monotherapy or in combination with endothelin receptor antagonists (ERA’s), for the treatment of adult patients with PAH with WHO Functional Class (FC) II to III to improve exercise capacity.³

ADEMPAS (riociguat) is also licensed for the treatment of adult patients with WHO functional class II to III with:

• inoperable CTEPH
• persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity.

What is Cardiovascular Disease (CVD)?

CVD is a broad category of disease which affect the heart and circulatory system. Specific CVD categories include CHD, heart failure and cerebrovascular disease (stroke). Ischaemic heart diseases were the second most common cause of mortality in the UK in 2017, accounting for 10.9% of deaths registered.⁴

For your patients requiring additional control of cholesterol

EZETROL is a once daily cholesterol absorption inhibitor used for the treatment of hypercholesterolaemia.⁵

Hypercholesterolaemia is characterised by very high level of LDL cholesterol (LDL-C) in the blood that leads to the blocking of blood vessels.⁶

The blocking of blood vessels causes cardiovascular (CV) events, such as heart attacks and strokes. EZETROL in combination with a statin was granted a license for the reduction in CV events in March 2016. EZETROL has proven lipid lowering efficacy when added to both atorvastatin 40 mg and atorvastatin 20 mg.^6-8

References

1. ESC Scientific Document Group; 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), European Heart Journal 2016; 37(1): 67-119
2. Simmoneau et al. Updated Clinical Classification of Pulmonary Hypertension. Am J Cardiol 2013; 62(25): D34-D41
3. ADEMPAS Summary of Product Characteristics
4. Office for National Statistics. Deaths registered in England and Wales (series DR): 2017
5. EZETROL Summary of Product Characteristics.
6. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosderosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011; 32(14): 1769-1818.
7. Bays et al. Efficacy and safety of Ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol 2013; 112: 1885-1895.
8. Leiter et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008; 102: 1495-150

Supporting documentation

ADEMPAS^® (riociguat)
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

EZETROL^® (ezetimibe)
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-ADE-00212 | Date of Preparation: September 2019